Trial Profile

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRTX 1719 (Primary)
Indications Adenocarcinoma; Cholangiocarcinoma; Mesothelioma; Nerve sheath neoplasms; Non-small cell lung cancer; Pancreatic cancer; Peripheral nervous system neoplasms; Solid tumours
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors Bristol-Myers Squibb; Mirati Therapeutics

Most Recent Events

10 Nov 2025 Trial protocol amended with addition of sub-study 5.
10 Nov 2025 Trial protocol amended with addition of sub-study 5.
10 Nov 2025 Planned number of patients changed from 320 to 336.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com